Cofetuzumab pelidotin, CAS 1869937-48-3

Product Description: Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Marc Damelin, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017 Jan 11;9(372):eaag2611. /[2]Chao Kong, et al. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Mol Cancer Ther. 2023 Oct 2;22(10):1128-1143. /[3]Masaru Katoh. Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis. nn Transl Med. 2017 Dec;5(23):462.

CAS Number: 1869937-48-3

Molecular Weight: N/A

Compound Purity: 99.67

Research Area: Cancer

Solubility: H2O

Target: Antibody-Drug Conjugates (ADCs);Microtubule/Tubulin

• Artikelnummer: MEXHY-P99829-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99829-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated